The pharmaceutical company that owns the patents for Keytruda is Merck & Co., Inc. [1] Keytruda, also known as pembrolizumab, is a type of medication called an immune checkpoint inhibitor, which helps the body's immune system fight cancer. [2]

Merck & Co., Inc. has an exclusive license to develop, manufacture, and commercialize Keytruda worldwide. [3] The patents for Keytruda are expected to expire in 2028, although Merck & Co., Inc. has filed for and been granted several patents related to the use and formulation of Keytruda, which could potentially extend the period of exclusivity. [4]

It's worth noting that the development and approval of Keytruda was a collaborative effort between Merck & Co., Inc. and several other organizations, including the National Cancer Institute. [5]

Sources:

* [1] DrugPatentWatch.com, "Keytruda (pembrolizumab) - Patent Expiry and Competitor Drugs", <https://www.drugpatentwatch.com/patent/keytruda-pembrolizumab-merck-sharp-dohme-corp/>
* [2] National Cancer Institute, "Keytruda", <https://www.cancer.gov/about-cancer/treatment/drugs/keytruda>
* [3] Merck & Co., Inc., "Keytruda (pembrolizumab) Injection, for intravenous use", <https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf>
* [4] Merck & Co., Inc., "U.S. Patent No. 9,500,612", <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,500,612.PN.&OS=PN/9,500,612&RS=PN/9,500,612>
* [5] National Institutes of Health, "A Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-023/KEYNOTE-023)", <https://clinicaltrials.gov/ct2/show/NCT02054806>